A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

Phase 3 Completed 101 enrolled Georgetown University GlaxoSmithKline · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The hope of this study is to gather data and information about the tolerability and effectiveness of Lexiva versus Sustiva in patients who have have been generally underrepresented in clinical trials.

Timeline

Start: 2008-07
Primary completion: 2010-08
Completion: 2011-07

Publications

Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, Felizarta F, Hao R, Ross L, Stancil B, Pappa K, Ha B; SUPPORT Study Team. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naive, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis. 2013 Jun 7;13:269. doi: 10.1186/1471-2334-13-269.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Efavirenz	Other / unclassified	600 mg	—
Subject	Fosamprenavir	Small molecule	1400 mg	—
Background	Abacavir	Other / unclassified	600 mg	—
Background	Lamivudine	Other / unclassified	300 mg	—
Background	Ritonavir	Other / unclassified	100 mg	—

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

Summary

Timeline

Publications

Drugs

Indications